33 Broadwick Street
London W1F 0DQ
United Kingdom
44 71 6676 6461
https://compasspathways.com
Sector(s): Healthcare
Industry: Medical Care Facilities
Full-time employees: 181
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. George Jay Goldsmith | Chairman & Co-founder | 826.37k | N/A | 1954 |
Mr. Kabir Nath M.A., M.B.A. | CEO & Director | 952.19k | N/A | 1965 |
Dr. Ekaterina Malievskaia M.D. | Co-Founder, Chief Innovation Officer & Exec. Director | 567.91k | N/A | 1967 |
Mr. Matthew Owens | Gen. Counsel & Chief Legal Officer | 659.53k | N/A | 1978 |
Mr. Michael F. Falvey | Chief Financial Officer | N/A | N/A | 1959 |
Dr. Greg Ryslik Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
Mr. Stephen D. Schultz | Sr. VP of Investor Relations | N/A | N/A | N/A |
Mr. Christopher Williams | Chief Communications Officer | N/A | N/A | N/A |
Ms. Anne Benedict | Chief People Officer | N/A | N/A | N/A |
Mr. Lars Christian Wilde | Sr. Advisor | N/A | N/A | 1985 |
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.